1.Reasons and Countermeasures of Discrepancy of the Account in Inventory Management of Automatic Oral Single Dose Drug Dispensing Machine
Hang HUANG ; Liman QIAO ; Shishi ZHENG ; Shihui BAO
China Pharmacy 2015;(25):3592-3594
OBJECTIVE:To explore the reasons and countermeasures of discrepancy of the account in inventory management of automatic single dose drug dispensing machine. METHODS:The discrepancy information of using sub charter in the process of inventory management from Feb. to Jun. 2014(before management)was collected,the causes were analyzed and countermeasures were put forward and carried out;then management results were evaluated via the discrepancy information from Jul. to Nov. 2014 (after management). RESULTS & CONCLUSIONS:For the relative discrepancy factors such as peeling medicine,adding medi-cine and recording information,etc.,which appeared in each link,the management was strengthened in terms of drug,machine and personnel like limiting scattered drug product rules,modifying the machine parameters settings,strengthening the training and testing of machine operators;and deliver inside account discrepancy rate was decreased from 3.34% to 0.79%. Improvement of the relative system with effective countermeasures can reduce the account sub charter discrepancy rate.
2.The efficacy of postoperative radiotherapy in stage Ⅲ(N 2) non-small cell lung cancer: a meta analysis
Lixian LING ; Shishi ZHOU ; Hongjuan ZHENG ; Ruihua YIN ; Mengjun TANG ; Jianfei FU
Chinese Journal of Radiation Oncology 2023;32(4):293-300
Objective:To conduct meta analysis to compare the effect of complete resection with or without postoperative radiotherapy (PORT) on survival in stage Ⅲ(N 2) non-small cell lung cancer (NSCLC). Methods:Relevant studies of the efficacy of PORT for stage Ⅲ(N 2) NSCLC were searched from Wanfang Data, PubMed, and Cochrane Library from January 2006 to January 2022. Literature screening, extraction of information and assessment of the risk of bias of the included literature was carried out by two independent researchers. Meta analysis was performed using R4.0.3 software. Results:A total of 12 publications consisting of 2992 patients were included, 1479 cases in the PORT group and 1513 cases in the control group. PORT improved the overall survival (OS) and disease free survival (DFS) compared to the control group. Fixed-effects model meta analysis of 6 randomized controlled trials showed that PORT did not significantly reduce the risk of death ( HR=0.98, 95% CI: 0.80-1.20). Fixed-effects model meta analysis of 6 retrospective studies showed that PORT improved prognosis ( HR=0.68, 95% CI: 0.59-0.79). PORT could improve OS of patients with multiple (station) metastasis of ipsilateral mediastinum and / or submandibular lymph nodes ( HR=0.89, 95% CI: 0.80-0.99). Conclusions:PORT could improve OS and DFS in stage Ⅲ(N 2) NSCLC. A trend towards benefit can be observed in the subgroup with multiple/multi-station N2 metastasis.
3.Immune Checkpoint Inhibitors Related Cystoureteritis: A Case Report and Literature Review.
Shishi LI ; Ke ZHENG ; Yan XU ; Mengzhao WANG
Chinese Journal of Lung Cancer 2023;26(9):709-716
A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient's symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment.
.
Humans
;
Immune Checkpoint Inhibitors/therapeutic use*
;
Lung Neoplasms/pathology*
;
Adenocarcinoma of Lung/drug therapy*
;
Tomography, X-Ray Computed